Although no published papers assessed the circulating sCD8 levels in cancer patients on PD-1/PD-L1 inhibitors, lower baseline sCD8 was previously shown in responders to immunotherapy with interferon-alpha (IFN-α) [36] and higher on-treatment sCD8—in patients with progressive disease dosed with IFN-γ [37]. This evidence concerns the gene CD274 and cancer.